Watch On You-Tube: About The CAN-BIND Study

Depression: Need for Improved Treatment

The CAN-BIND study aims to take the guess work out of psychiatric treatment for depression, by finding clear and objective ways of matching the right treatment to the right patient for various types of depression.

Major depression (also called clinical depression), affects close to 2,000,000 Canadians annually and is the leading cause of time lost from work, more than cancer or heart disease. Depression is also a major cause of mortality, particularly in young people, through suicide.

All ages, ethnicities, and socioeconomic groups are vulnerable to depression, and when it occurs, it can worsen the outcome for other co-existing medical disorders. Many treatments exist, but there are no specific ways to match a particular treatment—medication, psychotherapy, or other treatment—to a specific person, based on either biological tests, psychological styles, or any other feature of the person affected.

As a result, treatments are chosen that have been proven effective in large groups of people – but for the individual, the first treatment is the right one only about half the time.

Our Vision

We want to help reduce the impact of depression and its treatment by identifying “biomarkers”; these are biological and clinical characteristics that will help guide treatment selection. We are doing this by conducting a cross-Canada study of people being treated with standard medication for depression, but also getting a variety of blood tests, questionnaires, and MRI scans. Our primary funder include the Ontario Brain Institute (OBI), and other key partners include patient advocacy organizations particularly Mood Disorders Association of Ontario (MDAO).

Find Out More

Please see below for more details about the study: